In the May 2002 issue of the Journal, in the article entitled “Germline Alterations of the RNASEL Gene, a Candidate HPC1 Gene at 1q25, in Patients and Families with Prostate Cancer,” by Rökman et al. (70:1299–1304), four of the odds ratios and their corresponding 95% CI figures were incorrect. The corrected table 3 is shown here. The authors regret these errors and thank Professor Henrik Grönberg for bringing these mistakes to their attention.
Table 3.
Association of the Truncating Mutation E265X and the Missense variant R462Q of the RNASEL Gene with Patients with BPH, Unselected PRCA, or HPC
| Patient or Family Sample and Mutation | No. of Carriers/Total (Frequency) | OR | 95% CI | P |
| E265X: | ||||
| Controls | 10/566 (1.8%) | 1.00 | … | … |
| Patients with BPH | 7/223 (3.1%) | 1.80 | .68–4.79 | .24 |
| Patients with unselected PRCA | 10/492 (2.0%) | 1.15 | .48–2.80 | .75 |
| All patients with HPC | 5/116 (4.3%) | 2.51 | .84–7.47 | .1 |
| Two affecteds | 1/64 (1.6%) | .88 | .11–7.01 | .91 |
| Three affecteds | 2/31 (6.5%) | 3.83 | .80–18.31 | .09 |
| Four or more affecteds | 2/21 (9.5%) | 5.85 | 1.20–28.87 | .03a |
| R462Q homozygotes: | ||||
| Controls | 23/176 (13.1%) | 1.00 | … | … |
| Patients with unselected PRCA | 24/167 (14.4%) | 1.12 | .60–2.07 | .73 |
| All patients with HPC | 15/66 (22.7%) | 1.96 | .95–4.03 | .07 |
| Two affecteds | 2/19 (10.5%) | .78 | .17–3.61 | .75 |
| Three affecteds | 7/26 (26.9%) | 2.45 | .93–6.47 | .07 |
| Four or more affecteds | 6/21 (28.6%) | 2.66 | .94–7.55 | .07 |
a
Statistically significant.